Adjuvant system AS01: from mode of action to effective vaccines

REFERENCES

• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287–293. doi: 10.1038/nri2510
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Laupèze B, Di Pasquale A, et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16(1):55–63. doi: 10.1080/14760584.2016.1213632
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Malaria vaccine implementation programme [internet] [cited 2023 Mar 08] Available from: https://www.who.int/initiatives/malaria-vaccine-implementation-programme
   Google Scholar
• Praet N, Asante KP, Bozonnat MC, et al. Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up. Malar J. 2022;21(1):132. doi: 10.1186/s12936-022-04144-3
   PubMed Web of Science ®Google Scholar
• World Health Organization. Full evidence report on the RTS,S/AS01 malaria vaccine. SAGE Yellow Book for October 2021. 5.1 malaria [internet] [cited 2022 Mar 08]. Available from: https://cdn.who.int/media/docs/default-source/immunization/mvip/full-evidence-report-on-the-rtss-as01-malaria-vaccine-for-sage-mpag-(sept2021).pdf?sfvrsn=c9737be_5
   Google Scholar
• Izurieta HS, Wu X, Forshee R, et al. Recombinant zoster vaccine (shingrix): real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis. 2021;73(6):941–948. doi: 10.1093/cid/ciab125
   PubMed Web of Science ®Google Scholar
• Lu A, Sun Y, Porco TC, et al. Effectiveness of the recombinant zoster vaccine for herpes zoster ophthalmicus in the United States. Ophthalmology. 2021;128(12):1699–1707. doi: 10.1016/j.ophtha.2021.04.017
   PubMed Web of Science ®Google Scholar
• Mbinta JF, Nguyen BP, Awuni PMA, et al. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Lancet Healthy Longev. 2022;3:e263–e275. doi: 10.1016/S2666-7568(22)00039-3
   PubMedGoogle Scholar
• Okoli GN, Al-Yousif Y, Reddy VK, et al. The number needed to vaccinate (NNV) against herpes zoster: a systematic review with meta-analysis. Infect Dis (Lond). 2022;54(5):356–366. doi: 10.1080/23744235.2021.2018493
   PubMed Web of Science ®Google Scholar
• Sun Y, Jackson K, Dalmon CA, et al. Effectiveness of the recombinant zoster vaccine among kaiser permanente hawaii enrollees aged 50 and older: a retrospective cohort study. Vaccine. 2021;39(29):3974–3982. doi: 10.1016/j.vaccine.2021.05.056
   PubMed Web of Science ®Google Scholar
• Sun Y, Kim E, Kong CL, et al. Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study. Clin Infect Dis. 2021;73(6):949–956. doi: 10.1093/cid/ciab121
   PubMed Web of Science ®Google Scholar
• Xia Y, Zhang X, Zhang L, et al. Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis. Front Immunol. 2022;13:978203. doi: 10.3389/fimmu.2022.978203
   PubMed Web of Science ®Google Scholar
• Strezova A, Diez-Domingo J, Al Shawafi K, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis. 2022;9(10):ofac485. doi: 10.1093/ofid/ofac485
   PubMed Web of Science ®Google Scholar
• Garçon N, Di Pasquale A. From discovery to licensure, the Adjuvant System story. Hum. Vaccin. Immunother. 2017;13:19–33. doi: 10.1080/21645515.2016.1225635
   PubMed Web of Science ®Google Scholar
• Fortpied J, Collignon S, Moniotte N, et al. The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01. Malar J. 2020;19(1):202. doi: 10.1186/s12936-020-03253-1
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009;183(10):6186–6197. doi: 10.4049/jimmunol.0901474
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Koyama S, Nakagawa A, et al.. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host & Microbe. 2008;3(6):352–363. doi: 10.1016/j.chom.2008.05.003
   PubMed Web of Science ®Google Scholar
• Molteni M, Gemma S, Rossetti C. The role of toll-like receptor 4 in infectious and noninfectious inflammation. Mediators Inflamm. 2016;2016:6978936. doi: 10.1155/2016/6978936
   PubMed Web of Science ®Google Scholar
• Coler RN, Bertholet S, Moutaftsi M, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One. 2011;6(1):e16333. doi: 10.1371/journal.pone.0016333
   PubMed Web of Science ®Google Scholar
• Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid a as a TRIF-biased agonist of TLR4. Science. 2007;316(5831):1628–1632. doi: 10.1126/science.1138963
   PubMed Web of Science ®Google Scholar
• Welsby I, Detienne S, N’Kuli F, et al. Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21. Front Immunol. 2016;7:663. doi: 10.3389/fimmu.2016.00663
   PubMed Web of Science ®Google Scholar
• Detienne S, Welsby I, Collignon C, et al. Central role of CD169(+) lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01. Sci Rep. 2016;6:39475. doi: 10.1038/srep39475
   PubMed Web of Science ®Google Scholar
• Coccia M, Collignon C, Herve C, et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ Vaccines. 2017;2(1):25. doi: 10.1038/s41541-017-0027-3
   PubMed Web of Science ®Google Scholar
• Dendouga N, Fochesato M, Lockman L, et al. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012;30(20):3126–3135. doi: 10.1016/j.vaccine.2012.01.088
   PubMed Web of Science ®Google Scholar
• Thaiss CA, Levy M, Itav S, et al. Integration of innate immune signaling. Trends Immunol. 2016;37(2):84–101. doi: 10.1016/j.it.2015.12.003
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193(4):1920–1930. doi: 10.4049/jimmunol.1400948
   PubMed Web of Science ®Google Scholar
• Bosteels C, Fierens K, De Prijck S, et al. CCR2- and Flt3-Dependent inflammatory conventional type 2 dendritic cells are necessary for the induction of adaptive immunity by the human vaccine Adjuvant System AS01. Front Immunol. 2021;11:606805. doi: 10.3389/fimmu.2020.606805
   PubMed Web of Science ®Google Scholar
• Palmer EM, van Seventer GA. Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals. J Immunol. 1997;158(6):2654–2662. doi: 10.4049/jimmunol.158.6.2654
   PubMed Web of Science ®Google Scholar
• Dutton EE, Gajdasik DW, Willis C, et al. Peripheral lymph nodes contain migratory and resident innate lymphoid cell populations. Sci Immunol. 2019;4(35):eaau8082. doi: 10.1126/sciimmunol.aau8082
   PubMed Web of Science ®Google Scholar
• Van Maele L, Fougeron D, Cayet D, et al. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01. Eur J Immunol. 2019;49(12):2134–2145. doi: 10.1002/eji.201948234
   PubMed Web of Science ®Google Scholar
• Silva M, Kato Y, Melo MB, et al. A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. Science Immunol. 2021;6:eabf1152. doi: 10.1126/sciimmunol.abf1152
   PubMed Web of Science ®Google Scholar
• Burny W, Callegaro A, Bechtold V, et al. Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans. Front Immunol. 2017;8:943. doi: 10.3389/fimmu.2017.00943
   PubMed Web of Science ®Google Scholar
• van den Berg RA, Coccia M, Ballou WR, et al. Predicting RTS,S vaccine-mediated protection from transcriptomes in a malaria-challenge clinical trial. Front Immunol. 2017;8:557. doi: 10.3389/fimmu.2017.00557
   PubMed Web of Science ®Google Scholar
• Bradley LM, Dalton DK, Croft M. A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol. 1996;157(4):1350–1358. doi: 10.4049/jimmunol.157.4.1350
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–189. doi: 10.1189/jlb.0603252
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Marchant A, Levy J, et al. Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial. Clin Immunol. 2016;169:16–27. doi: 10.1016/j.clim.2016.05.007
   PubMed Web of Science ®Google Scholar
• De Mot L, Bechtold V, Bol V, et al. Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signature. Sci Transl Med. 2020;12. doi: 10.1126/scitranslmed.aay8618
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Heineman TC, Lal H, et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis. 2018;217(11):1750–1760. doi: 10.1093/infdis/jiy095
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Davis MG, Steenackers K, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial. J Infect Dis. 2023;227(6):761–772. doi: 10.1093/infdis/jiac327
   PubMed Web of Science ®Google Scholar
• Coccia M, Burny W, Demoitie MA, et al. Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses. PLoS One. 2022;17(11):e0276505. doi: 10.1371/journal.pone.0276505
   PubMed Web of Science ®Google Scholar
• Loos C, Coccia M, Didierlaurent AM, et al. Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design. NPJ Vaccines. 2023;8(1):34. doi: 10.1038/s41541-023-00613-1
   PubMed Web of Science ®Google Scholar
• Budroni S, Buricchi F, Cavallone A, et al. Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. NPJ Vaccines. 2021;6(1):78. doi: 10.1038/s41541-021-00337-0
   PubMed Web of Science ®Google Scholar
• Morrocchi E, van Haren S, Palma P, et al. Modeling human immune responses to vaccination in vitro. Trends Immunol. 2024;45(1):32–47. doi: 10.1016/j.it.2023.11.002
   PubMed Web of Science ®Google Scholar
• Smith CL, Richardson B, Rubsamen M, et al. Adjuvant AS01 activates human monocytes for costimulation and systemic inflammation. Vaccine. 2024;42(2):229–238. doi: 10.1016/j.vaccine.2023.12.010
   PubMed Web of Science ®Google Scholar
• World Health Organization. Malaria: The malaria vaccine implementation programme (MVIP). 2 March 2020. Q&A [internet] [cited 2022 Mar 08]. Available from:. https://www.who.int/news-room/questions-and-answers/item/malaria-vaccine-implementation-programme
   Google Scholar
• World Health Organization. Malaria vaccine: WHO position paper –March 2022. Wkly Epidemiol Rec. 2022;97 61–80.
   Google Scholar
• RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45. doi: 10.1016/S0140-6736(15)60721-8
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Mosquirix H-W-2300. Product information [internet] [cited 2024 Feb 16]. Available from: https://www.ema.europa.eu/en/glossary/product-information
   Google Scholar
• Dicko A, Ouedraogo JB, Zongo I, et al. Seasonal vaccination with RTS,S/AS01(E) vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. Lancet Infect Dis. 2023;24:75–86. doi: 10.1016/S1473-3099(23)00368-7
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Malaria. Appendix A: Malaria Lifecycle. [internet] [cited 2024 July 03]. Available from: https://www.cdc.gov/malaria/php/surveillance/appendix-a-malaria-lifecycle.html
   Google Scholar
• Beeson JG, Kurtovic L, Valim C, et al. The RTS,S malaria vaccine: Current impact and foundation for the future. Sci Transl Med. 2022;14(671):eabo6646. doi: 10.1126/scitranslmed.abo6646
   PubMed Web of Science ®Google Scholar
• Ockenhouse CF, Regules J, Tosh D, et al. Ad35.CS.01 - RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naïve adults. PLoS One. 2015;10(7):e0131571. doi: 10.1371/journal.pone.0131571
   PubMed Web of Science ®Google Scholar
• Kazmin D, Nakaya HI, Lee EK, et al. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. Proc Natl Acad Sci USA. 2017;114:2425–2430. doi: 10.1073/pnas.1621489114
   PubMed Web of Science ®Google Scholar
• Suscovich TJ, Fallon JK, Das J, et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. Sci Transl Med. 2020;12(553):12. doi: 10.1126/scitranslmed.abb4757
   Web of Science ®Google Scholar
• Seaton KE, Spreng RL, Abraha M, et al. Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection. NPJ Vaccines. 2021;6(1):110. doi: 10.1038/s41541-021-00372-x
   PubMed Web of Science ®Google Scholar
• Pallikkuth S, Chaudhury S, Lu P, et al. A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses. eLife. 2020;9. doi: 10.7554/eLife.51889
   PubMed Web of Science ®Google Scholar
• Nielsen CM, Ogbe A, Pedroza-Pacheco I, et al. Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. Cell Rep Med. 2021;2:100207. doi: 10.1016/j.xcrm.2021.100207
   PubMedGoogle Scholar
• Young WC, Carpp LN, Chaudhury S, et al. Comprehensive data integration approach to assess immune responses and correlates of RTS,S/AS01-mediated protection from malaria infection in controlled human malaria infection trials. Front. Big Data. 2021;4:672460. doi: 10.3389/fdata.2021.672460
   PubMedGoogle Scholar
• Moris P, Jongert E, van der Most RG. Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine. Hum Vaccin Immunother. 2018;14(1):17–27. doi: 10.1080/21645515.2017.1381809
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–1032. doi: 10.1056/NEJMoa1603800
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Eng J Med. 2015;372:2087–2096. doi: 10.1056/NEJMoa1501184
   PubMed Web of Science ®Google Scholar
• Shingrix Summary of Product Characteristics. [internet] [cited 2023 Sept 05]. Available from: https://www.ema.europa.eu/en/documents/product-information/shingrix-epar-product-information_en.pdf 2018
   Google Scholar
• Shingrix Prescribing Information [internet] [cited 2023 Sept 05]. Available from: https://www.fda.gov/media/108597/download
   Google Scholar
• Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged >/=19 Years: recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR. 2022;71:80–84. doi: 10.15585/mmwr.mm7103a2
   PubMed Web of Science ®Google Scholar
• Dagnew AF, Rausch D, Herve C, et al. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021;60(3):1226–1233. doi: 10.1093/rheumatology/keaa424
   PubMed Web of Science ®Google Scholar
• Hastie A, Catteau G, Enemuo A, et al. Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination. J Infect Dis. 2021;224(12):2025–2034. doi: 10.1093/infdis/jiaa300
   PubMed Web of Science ®Google Scholar
• Chlibek R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥50 years of age. J Infect Dis. 2013;208:1953–1961. doi: 10.1093/infdis/jit365
   PubMed Web of Science ®Google Scholar
• Weinberg A, Kroehl ME, Johnson MJ, et al. comparative immune responses to licensed herpes zoster vaccines. J Infect Dis. 2018;218(suppl_2):S81–S87. doi: 10.1093/infdis/jiy383
   PubMedGoogle Scholar
• Levin MJ, Kroehl ME, Johnson MJ, et al. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest. 2018;128(10):4429–4440. doi: 10.1172/JCI121484
   PubMed Web of Science ®Google Scholar
• Laing KJ, Ford ES, Johnson MJ, et al. Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity. J Clin Invest. 2023. doi: 10.1172/JCI172634 133 23
   PubMed Web of Science ®Google Scholar
• Park SY, Levin MJ, Canniff J, et al. Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines. NPJ Vaccines. 2022;7(1):123. doi: 10.1038/s41541-022-00545-2
   PubMed Web of Science ®Google Scholar
• Savic M, Penders Y, Shi T, et al. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2023;17(1):e13031. doi: 10.1111/irv.13031
   PubMed Web of Science ®Google Scholar
• Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 2015;7:309ra162. doi: 10.1126/scitranslmed.aac4241
   PubMed Web of Science ®Google Scholar
• Rossey I, McLellan JS, Saelens X, et al. Clinical potential of prefusion RSV F-specific antibodies. Trends Microbiol. 2018;26(3):209–219. doi: 10.1016/j.tim.2017.09.009
   PubMed Web of Science ®Google Scholar
• Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis. 2004;189(2):233–238. doi: 10.1086/380907
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis. 1998;177(2):463–466. doi: 10.1086/517376
   PubMed Web of Science ®Google Scholar
• Looney RJ, Falsey AR, Walsh E, et al. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J Infect Dis. 2002;185(5):682–685. doi: 10.1086/339008
   PubMed Web of Science ®Google Scholar
• Cherukuri A, Patton K, Gasser RA, Jr., et al. Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin Vac Immunol. 2013;20:239–247. doi: 10.1128/CVI.00580-12
   PubMed Web of Science ®Google Scholar
• Sacconnay L, De Smedt J, Rocha-Perugini V, et al. The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains. Sci Transl Med. 2023;15(710):eadg6050. doi: 10.1126/scitranslmed.adg6050
   PubMed Web of Science ®Google Scholar
• Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N. Engl. J. Med. 2023;388:595–608. doi: 10.1056/NEJMoa2209604
   PubMed Web of Science ®Google Scholar
• Ison MG, Papi A, Athan E, et al. Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis. 2024;78(6):1732–1744. doi: 10.1093/cid/ciae010
   PubMed Web of Science ®Google Scholar
• US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vccine for older adults. [03 May 2023, cited 2023 Jun 19]. Available from: https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/
   Google Scholar
• European Medicines Agency. Arexvy. [cited 2023, Sept 23]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy
   Google Scholar
• Press release. GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults approved in Canada [internet] [cited 2023 Aug 04]. Available from: https://ca.gsk.com/en-ca/media/press-releases/gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults-approved-in-canada/
   Google Scholar
• Japan’s Ministry of Health, Labour and Welfare approves GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults [internet] [cited 2023 Sept 23]. Available from: https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-approves-gsk-s-arexvy/
   Google Scholar
• Herve C, Laupeze B, Del Giudice G, et al. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. 2019;4(1):39. doi: 10.1038/s41541-019-0132-6
   PubMed Web of Science ®Google Scholar
• Burny W, Marchant A, Herve C, et al. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. Vaccine. 2019;37(14):2004–2015. doi: 10.1016/j.vaccine.2019.02.015
   PubMed Web of Science ®Google Scholar
• Di Pasquale A, Preiss S, Tavares Da Silva F, et al. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel). 2015;3:320–343. doi: 10.3390/vaccines3020320
   PubMed Web of Science ®Google Scholar
• Baay M, Bollaerts K, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults. Vaccine. 2018;36(29):4207–4214. doi: 10.1016/j.vaccine.2018.06.004
   PubMed Web of Science ®Google Scholar
• RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Eng J Med. 2012;367:2284–2295. doi: 10.1056/NEJMoa1208394
   PubMed Web of Science ®Google Scholar
• RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. New Eng J Med. 2011;365:1863–1875. doi: 10.1056/NEJMoa1102287
   PubMed Web of Science ®Google Scholar
• Guerra Mendoza Y, Garric E, Leach A, et al. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Hum Vaccin Immunother. 2019;15(10):2386–2398. doi: 10.1080/21645515.2019.1586040
   PubMed Web of Science ®Google Scholar
• Yihunie W, Kebede B, Tegegne BA, et al. Systematic review of safety of RTS,S with AS01 and AS02 Adjuvant Systems using data from randomized controlled trials in infants, children, and adults. Clin Pharmacol. 2023;15:21–32. doi: 10.2147/CPAA.S400155
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Chen M, et al. Impact of reactogenicity after two doses of recombinant zoster vaccine upon physical functioning and quality of life: an open phase III trial in older adults. J. Gerontol. A Biol Sci Med Sci. 2021;76:485–490. doi: 10.1093/gerona/glaa127
   PubMed Web of Science ®Google Scholar
• Tavares-Da-Silva F, Co MM, Dessart C, et al. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. Vaccine. 2020;38(18):3489–3500. doi: 10.1016/j.vaccine.2019.11.058
   PubMed Web of Science ®Google Scholar
• Hesse EM, Shimabukuro TT, Su JR, et al. Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix) - United States, October 2017-June 2018. MMWR. 2019;68:91–94. doi: 10.15585/mmwr.mm6804a4
   Web of Science ®Google Scholar
• Lopez-Fauqued M, Co-van der Mee M, Bastidas A, et al. Safety profile of the adjuvanted recombinant zoster vaccine in immunocompromised populations: an overview of six trials. Drug Saf. 2021;44(7):811–823. doi: 10.1007/s40264-021-01076-w
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Fact sheet. Tuberculosis [internet] [updated 7 Nov 2023 cited 2023 Deb 16]. Available from https://www.who.int/news-room/fact-sheets/detail/tuberculosis 2023.
   Google Scholar
• Scriba TJ, Dinkele R, Warner DF, et al. Challenges in TB research. J Exp Med. 2022;219. doi: 10.1084/jem.20221334 12
   PubMed Web of Science ®Google Scholar
• Stewart P, Patel S, Comer A, et al. Role of B vells in Mycobacterium tuberculosis infection. Vaccines (Basel). 2023;11. doi: 10.3390/vaccines11050955
   PubMed Web of Science ®Google Scholar
• Tait DR, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429–2439. doi: 10.1056/NEJMoa1909953
   PubMed Web of Science ®Google Scholar
• Ouaked N, Demoitie MA, Godfroid F, et al. Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72/AS01. Tuberculosis (Edinb). 2023;143:102425. doi: 10.1016/j.tube.2023.102425
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Forgus S, De Boever F, et al. Improved CD4+ T cell responses to mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine. 2013;31(17):2196–2206. doi: 10.1016/j.vaccine.2012.05.035
   PubMed Web of Science ®Google Scholar
• Penn-Nicholson A, Geldenhuys H, Burny W, et al. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine. 2015;33(32):4025–4034. doi: 10.1016/j.vaccine.2015.05.088
   PubMed Web of Science ®Google Scholar
• Day CL, Tameris M, Mansoor N, et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med. 2013;188(4):492–502. doi: 10.1164/rccm.201208-1385OC
   PubMed Web of Science ®Google Scholar
• Lalvani A, Moris P, Voss G, et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis. 1999;180(5):1656–1664. doi: 10.1086/315074
   PubMed Web of Science ®Google Scholar
• Cohen KW, De Rosa SC, Fulp WJ, et al. A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses. Sci Transl Med. 2023;15(697):eadf3309. doi: 10.1126/scitranslmed.adf3309
   PubMed Web of Science ®Google Scholar
• Callegaro A, Burny W, Herve C, et al. association between immunogenicity and reactogenicity: a post hoc analysis of 2 phase 3 studies with the adjuvanted recombinant zoster vaccine. J Infect Dis. 2022;226(11):1943–1948. doi: 10.1093/infdis/jiab536
   PubMed Web of Science ®Google Scholar
• Laupeze B, Vassilev V, Badur S. A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments. Expert Rev Gastroenterol Hepatol. 2023;17(11):1135–1147. doi: 10.1080/17474124.2023.2268503
   PubMed Web of Science ®Google Scholar
• Laupeze B, Del Giudice G, Doherty MT, et al. Vaccination as a preventative measure contributing to immune fitness. NPJ vaccines. 2021;6:93. doi: 10.1038/s41541-021-00354-z
   PubMed Web of Science ®Google Scholar
• Smolen K, Bechtold V, Burny W, et al. AS01B-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes. Presentation at: 5th International Symposium on Trained Immunity; 2023 May 29-31, Naples (Italy). Abstract E-Book [page 28]. Available from: https://www.innateimmunememory.org/images/Abstract%20International%20Symposium%20on%20Innate%20Immune%20Memory.pdf
   Google Scholar
• Dagenais A, Villalba-Guerrero C, Olivier M Trained immunity: A “new” weapon in the fight against infectious diseases. Front Immunol. 2023;14:1147476. doi: 10.3389/fimmu.2023.1147476
   PubMed Web of Science ®Google Scholar
• Moon JE, Greenleaf ME, Regules JA, et al. A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge. Vaccine. 2021;39(43):6398–6406. doi: 10.1016/j.vaccine.2021.09.024
   PubMed Web of Science ®Google Scholar
• Samuels AM, Ansong D, Kariuki SK, et al. Efficacy of RTS,S/AS01(E) malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial. Lancet Infect Dis. 2022;22:1329–1342. doi: 10.1016/S1473-3099(22)00273-0
   PubMedGoogle Scholar
• Desikan R, Padmanabhan P, Kierzek AM, et al. Mechanistic models of COVID-19: insights into disease progression, vaccines, and therapeutics. Int J Antimicrob Agents. 2022;60(1):106606. doi: 10.1016/j.ijantimicag.2022.106606
   PubMed Web of Science ®Google Scholar
• Bruxvoort KJ, Ackerson B, Sy LS, et al. Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults. J Infect Dis. 2021;225:1915–1922. doi: 10.1093/infdis/jiab633
   Web of Science ®Google Scholar